Emerging from the leishmaniasis L205 lead optimization series after showing great efficacy in vivo in both mouse and hamster models for visceral leishmaniasis, DNDI-6174 was nominated as a pre-clinical candidate for visceral leishmaniasis in 2019. DNDI-6174 presents a new mode of action among compounds in DNDi’s leishmaniasis portfolio as well as a predicted low human dose and a very promising safety margin.

Project updates

2020

Further characterization of DNDI-6174 and preparations to initiate pre-clinical activities continued in 2020. With support from Japan’s Global Health Innovative Technology Fund (GHIT Fund), DNDi and Eisai will start collaborating in Q2 2021 to conduct pre-clinical development activities and prepare the way for future Phase I clinical studies in healthy human volunteers. 

2019

Planning is underway to start pre-clinical activities in 2020.